These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Blockade of thromboxane and the prevention of eicosanoid-induced sudden death in mice. Darius H; Lefer AM Proc Soc Exp Biol Med; 1985 Nov; 180(2):364-8. PubMed ID: 2996012 [TBL] [Abstract][Full Text] [Related]
23. Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon Study. van der Meer J; Brutel de la Rivière A; van Gilst WH; Hillege HL; Pfisterer M; Kootstra GJ; Dunselman PH; Mulder BJ; Lie KI J Am Coll Cardiol; 1994 Nov; 24(5):1181-8. PubMed ID: 7930237 [TBL] [Abstract][Full Text] [Related]
24. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Hoet B; Falcon C; De Reys S; Arnout J; Deckmyn H; Vermylen J Blood; 1990 Feb; 75(3):646-53. PubMed ID: 2153424 [TBL] [Abstract][Full Text] [Related]
25. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687 [TBL] [Abstract][Full Text] [Related]
26. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694 [TBL] [Abstract][Full Text] [Related]
27. Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts. Hansen KJ; Howe HR; Edgerton TA; Faust KB; Kon ND; Geisinger KR; Meredith JH J Vasc Surg; 1986 Aug; 4(2):174-8. PubMed ID: 3735571 [TBL] [Abstract][Full Text] [Related]
28. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related]
29. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog. Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193 [TBL] [Abstract][Full Text] [Related]
30. Biosynthesis and pharmacological modulation of thromboxane in humans. Patrono C Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814 [TBL] [Abstract][Full Text] [Related]
31. Antiaggregatory effects of thromboxane receptor antagonists in vivo. Darius H; Lefer AM Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972 [TBL] [Abstract][Full Text] [Related]
32. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517 [TBL] [Abstract][Full Text] [Related]